{"created":"2023-05-15T16:49:00.739630+00:00","id":26269,"links":{},"metadata":{"_buckets":{"deposit":"267132f3-9415-42e0-bbc2-7577b261ec1c"},"_deposit":{"created_by":6,"id":"26269","owners":[6],"pid":{"revision_id":0,"type":"depid","value":"26269"},"status":"published"},"_oai":{"id":"oai:nagasaki-u.repo.nii.ac.jp:00026269","sets":["8:9"]},"author_link":["112259","112261","112265","112266","112267","112270","112258","112264","112262","112263","112269","112257","112268","112260"],"item_2_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2020-12-17","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"2","bibliographicPageEnd":"8","bibliographicPageStart":"1","bibliographicVolumeNumber":"14","bibliographic_titles":[{"bibliographic_title":"Biomedical Reports"}]}]},"item_2_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Gastroesophageal reflux disease (GERD) in systemic sclerosis (SSc) can significantly reduce a patient's quality of life. GERD in SSc is occasionally resistant to conventional anti-acid treatment. Vonoprazan is an H+/K+-ATPase blocker that is approved in Japan for treatment of GERD. The aim of the present study was to evaluate the efficacy of vonoprazan in SSc-related GERD. The frequency scale for symptoms of GERD (FSSG) scores were collected before and after vono-prazan treatment in 15 SSc patients with GERD. Additionally, endoscopic esophagogastroduodenoscopy was performed in select patients. Conventional proton pump \ninhibitors or hista-mine-2 receptor antagonists had been previously administered in 93% (14/15) of the patients. Although the baseline esophago-gastroduodenoscopy examination did not show severe erosion in the majority of patients,the mean total FSSG score before vonoprazan treatment was notably high (25.2±10.7) compared to a normal score of <8. After vonoprazan treatment, the FSSG score decreased to 9.6±7.0. The mean improvement rate of the total FSSG, acid reflux and dysmotility scores were 60.8±21.2% (P=0.0004), 67.3±24.8% (P<0.0001) and 55.4±26.0% (P=0.0022), respectively.These results suggest that vonoprazan may be a potentially effective treatment for GERD in patients with SSc.","subitem_description_type":"Abstract"}]},"item_2_description_63":{"attribute_name":"引用","attribute_value_mlt":[{"subitem_description":"Biomedical Reports, 14(2),  pp.1-8; 2020","subitem_description_type":"Other"}]},"item_2_publisher_33":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Spandidos Publications"}]},"item_2_relation_12":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"10.3892/br.2020.1401","subitem_relation_type_select":"DOI"}}]},"item_2_rights_13":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"© Tabuchi et al. This is an open access article distributed under the terms of Creative Commons Attribution License. "}]},"item_2_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"2049-9434","subitem_source_identifier_type":"ISSN"}]},"item_2_version_type_16":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Tabuchi, Maiko"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Minami, Hitomi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Akazawa, Yuko"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Ashida, Miwa"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Hara, Toshihide"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Ichinose, Kunihiro"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Kitayama, Moto"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Hashiguchi, Keiichi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Matsushima, Kayoko"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Yamaguchi, Naoyuki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Takeshima, Fuminao"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Kondo, Hisayoshi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Kawakami, Atsushi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Nakao, Kazuhiko"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2021-01-22"}],"displaytype":"detail","filename":"BioRes14_1.pdf","filesize":[{"value":"1.1 MB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"BioRes14_1.pdf ","url":"https://nagasaki-u.repo.nii.ac.jp/record/26269/files/BioRes14_1.pdf"},"version_id":"0df21ebc-2acd-48c0-ab3d-1e5b606c5b0f"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Frequency scale for symptoms of gastroesophageal reflux disease","subitem_subject_scheme":"Other"},{"subitem_subject":"Gastroesophageal reflux disease","subitem_subject_scheme":"Other"},{"subitem_subject":"Proton pump inhibitor","subitem_subject_scheme":"Other"},{"subitem_subject":"Systemic sclerosis","subitem_subject_scheme":"Other"},{"subitem_subject":"Vonoprazan      ,","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Use of vonoprazan for management of systemic sclerosis‑related gastroesophageal reflux disease","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Use of vonoprazan for management of systemic sclerosis‑related gastroesophageal reflux disease"}]},"item_type_id":"2","owner":"6","path":["9"],"pubdate":{"attribute_name":"公開日","attribute_value":"2021-01-22"},"publish_date":"2021-01-22","publish_status":"0","recid":"26269","relation_version_is_last":true,"title":["Use of vonoprazan for management of systemic sclerosis‑related gastroesophageal reflux disease"],"weko_creator_id":"6","weko_shared_id":-1},"updated":"2023-05-15T22:55:40.705698+00:00"}